{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T19:20:27Z","timestamp":1773170427745,"version":"3.50.1"},"reference-count":15,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,9,13]]},"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>The advent of immunotherapy has revolutionised the treatment of metastatic lung cancer and it has recently been established as the standard of care in the radical treatment of lung cancer. However, immune-related adverse events (IrAEs) frequently occur in patients treated with immunotherapy, and rare IrAEs continue to be identified. We report a case of immunotherapy-induced coeliac disease due to adjuvant durvalumab post-chemoradiotherapy in a patient receiving curative treatment for lung cancer. The patient had raised anti-tissue transglutaminase IgA and histological findings consistent with coeliac disease. This is the first published case report of probable immunotherapy-induced coeliac disease both with the immunotherapy drug durvalumab and in the curative lung cancer setting.<\/jats:p>","DOI":"10.1136\/bcr-2021-243406","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T12:57:44Z","timestamp":1632747464000},"page":"e243406","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy-induced coeliac disease in curative lung cancer"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-7092","authenticated-orcid":false,"given":"Hannah","family":"Walton","sequence":"first","affiliation":[{"name":"Edinburgh IBD Unit, NHS Lothian, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, NHS Lothian, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Shand","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, NHS Lothian, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-3400","authenticated-orcid":false,"given":"Shahida","family":"Din","sequence":"additional","affiliation":[{"name":"Edinburgh IBD Unit, NHS Lothian, Edinburgh, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,9,27]]},"reference":[{"key":"2025082803022123000_14.9.e243406.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937"},{"key":"2025082803022123000_14.9.e243406.2","unstructured":"Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation - guidance (TA578), 2019. Available: https:\/\/www.nice.org.uk\/guidance\/ta578"},{"key":"2025082803022123000_14.9.e243406.3","doi-asserted-by":"crossref","DOI":"10.1016\/0016-5085(92)91819-P","article-title":"Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue')","volume":"102","author":"Marsh","year":"1992","journal-title":"Gastroenterology"},{"key":"2025082803022123000_14.9.e243406.4","doi-asserted-by":"crossref","unstructured":"Fasano A , Catassi C . Celiac disease. N Engl J Med 2012.doi:10.1056\/NEJMcp1113994","DOI":"10.1056\/NEJMcp1113994"},{"key":"2025082803022123000_14.9.e243406.5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-306578"},{"key":"2025082803022123000_14.9.e243406.6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13281"},{"key":"2025082803022123000_14.9.e243406.7","doi-asserted-by":"crossref","first-page":"e00158","DOI":"10.14309\/crj.0000000000000158","article-title":"A celiac disease phenotype after checkpoint inhibitor exposure: an example of immune dysregulation after immunotherapy","volume":"6","author":"Arnouk","year":"2019","journal-title":"ACG Case Rep J"},{"key":"2025082803022123000_14.9.e243406.8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0694-x"},{"key":"2025082803022123000_14.9.e243406.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2013.01.015"},{"key":"2025082803022123000_14.9.e243406.10","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i4.405"},{"key":"2025082803022123000_14.9.e243406.11","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxp069"},{"key":"2025082803022123000_14.9.e243406.12","doi-asserted-by":"crossref","unstructured":"Fazal MW , Spain L , Ibraheim H , et al . Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea. Gut 2018;67.doi:10.1136\/gutjnl-2018-BSGAbstracts.131","DOI":"10.1136\/gutjnl-2018-BSGAbstracts.131"},{"key":"2025082803022123000_14.9.e243406.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8448"},{"key":"2025082803022123000_14.9.e243406.14","doi-asserted-by":"crossref","unstructured":"Brahmer JR , Lacchetti C , Schneider BJ . Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. J Clin Oncol 2018.doi:10.1200\/JCO.2017.77.6385","DOI":"10.1200\/JOP.18.00005"},{"key":"2025082803022123000_14.9.e243406.15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S2468-1253(20)30014-5","article-title":"British Society of gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis","volume":"5","author":"Powell","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-243406","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:02:27Z","timestamp":1756375347000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-243406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":15,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,27]]},"published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1136\/bcr-2021-243406"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-243406","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}